NAGIOS: RODERIC FUNCIONANDO

Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab): review

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab): review

Mostra el registre parcial de l'element

dc.contributor.author Oliveira, Camila-Carvalho de es
dc.contributor.author Brizeno, Luiz-André-Cavalcante es
dc.contributor.author Sousa, Fabrício Bitu es
dc.contributor.author Lima Mota, Mário Rogério es
dc.contributor.author Alves, Ana Paula es
dc.date.accessioned 2016-07-26T12:01:03Z
dc.date.available 2016-07-26T12:01:03Z
dc.date.issued 2016 es
dc.identifier.citation Oliveira, Camila-Carvalho de ; Brizeno, Luiz-André-Cavalcante ; Sousa, Fabrício Bitu ; Lima Mota, Mário Rogério ; Alves, Ana Paula. Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab): review. En: Medicina oral, patología oral y cirugía bucal. Ed inglesa, 2016, Vol. 21, No. 4: 431- es
dc.identifier.uri http://hdl.handle.net/10550/54791
dc.description.abstract Background: Denosumab, an anti-resorptive agent, IgG2 monoclonal antibody for human Receptor activator of nuclear factor-kappa B ligand (RANKL), has been related to the occurrence of osteonecrosis of the jaws. Thus, the aim of this study was to review the literature from clinical case reports, regarding the type of patient and the therapeutic approach used for osteonecrosis of the jaws induced by chronic use of Denosumab. Material and Methods: For this, a literature review was performed on PubMed, Medline and Cochrane databases, using the keywords “Denosumab” “anti-RANK ligand” and “Osteonecrosis of jaw”. To be included, articles should be a report or a serie of clinical cases, describing patients aged 18 years or over who used denosumab therapy and have received any therapy for ONJ. Results: Thirteen complete articles were selected for this review, totaling 17 clinical cases. The majority of ONJ cases, patients receiving Denosumab as treatment for osteoporosis and prostate cancer therapy. In most cases, patients affected by ONJ were women aged 60 or over and posterior mandible area was the main site of involvement. Diabetes pre-treatment with bisphosphonates and exodontia were the most often risk factors related to the occurrence of this condition. Systemic and local antibiotic therapy with or without surgical debridement was the most used treatment for ONJ resolution. Conclusions: It is concluded that the highest number of ONJ cases caused by the use of anti-RANKL agents occurred in female patients, aged 60 years or older, under treatment for osteoporosis and cancer metastasis, and the most affected region was the mandible posterior. en_US
dc.relation es
dc.subject Odontología es
dc.subject Ciencias de la salud es
dc.title Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab): review es
dc.type journal article es_ES
dc.subject.unesco UNESCO::CIENCIAS MÉDICAS es
dc.type.hasVersion VoR es_ES

Visualització       (641.3Kb)

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre parcial de l'element

Cerca a RODERIC

Cerca avançada

Visualitza

Estadístiques